Asia
Under terms of the agreement, Astellas will make an upfront cash payment of $80 million to CytomX.
A University of Florida chemistry professor who fled the United States after falling under investigation for his ties to academic institutions in China has been at the forefront of developing a diagnostic test for the novel coronavirus in China.
The company did not know of her intention to leave the U.S. for China. They did not know she had been gone until the Chinese media reported the story. She was terminated by Biogen this week.
The company has nine drug candidates in human clinical trials.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
Both compounds block integral viral mechanisms for SARS-CoV-2 replication and infection
Companies strengthen their leadership teams and board with this week’s Movers & Shakers.
FujiFilm itself has not commented on the reports from China, The Guardian noted.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
Zai Lab Limited announced the China National Medical Products Administration has accepted its supplemental New Drug Application for ZEJULA® as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
PRESS RELEASES